VIR Stock Overview
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Vir Biotechnology, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$10.13 |
52 Week High | US$27.48 |
52 Week Low | US$7.72 |
Beta | 0.42 |
1 Month Change | -11.37% |
3 Month Change | 0.70% |
1 Year Change | -55.96% |
3 Year Change | -79.56% |
5 Year Change | n/a |
Change since IPO | -27.75% |
Recent News & Updates
Recent updates
Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta
Feb 28Sticking With Vir Biotechnology
Jan 17Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Just Slashed This Year's Revenue Estimates By 37%
Aug 07Revenues Working Against Vir Biotechnology, Inc.'s (NASDAQ:VIR) Share Price Following 42% Dive
Jul 24Analysts Just Shaved Their Vir Biotechnology, Inc. (NASDAQ:VIR) Forecasts Dramatically
Feb 28Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Could Be 26% Below Their Intrinsic Value Estimate
Jan 07Vir Biotechnology: Focus On Hepatitis B Development Could End Up Paying Off
Oct 12Vir Biotech gains 12% as U.S. govt. inks multi-year deal worth up to $1B
Oct 04Vir begins dosing in mid-stage study of VIR-2218, VIR-3434 for hepatitis D virus
Sep 22Vir Biotechnology falls 15% on Q2 revenue miss impacted by ~$400M for potential write-offs
Aug 09Vir: Biotechnology's Best Near-Term Capital Gain Prospect
Jul 27Vir Biotechnology announces transition of chief scientific officer
Jul 14Shareholder Returns
VIR | US Biotechs | US Market | |
---|---|---|---|
7D | 0.4% | 0.9% | 0.4% |
1Y | -56.0% | 10.3% | 28.8% |
Return vs Industry: VIR underperformed the US Biotechs industry which returned 10.3% over the past year.
Return vs Market: VIR underperformed the US Market which returned 28.8% over the past year.
Price Volatility
VIR volatility | |
---|---|
VIR Average Weekly Movement | 7.8% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VIR has not had significant price volatility in the past 3 months.
Volatility Over Time: VIR's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2016 | 587 | Marianne De Backer | https://www.vir.bio |
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA.
Vir Biotechnology, Inc. Fundamentals Summary
VIR fundamental statistics | |
---|---|
Market cap | US$1.36b |
Earnings (TTM) | -US$615.06m |
Revenue (TTM) | US$86.18m |
15.9x
P/S Ratio-2.2x
P/E RatioIs VIR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VIR income statement (TTM) | |
---|---|
Revenue | US$86.18m |
Cost of Revenue | US$509.41m |
Gross Profit | -US$423.23m |
Other Expenses | US$191.83m |
Earnings | -US$615.06m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -4.55 |
Gross Margin | -491.10% |
Net Profit Margin | -713.69% |
Debt/Equity Ratio | 0% |
How did VIR perform over the long term?
See historical performance and comparison